UPL's Subsidiary UPL Brasil Gets Green Light to Sell Full Stake in Bioplanta JV for USD 20
UPL Limited's subsidiary, UPL do Brasil, received regulatory clearance on July 29, 2026, to sell its entire stake in joint venture Bioplanta Nutricao Vegetal for a nominal USD 20, with the deal set to close by July 31, 2026. Bioplanta, engaged in fertilizers and agrochemicals, reported FY25 revenue of USD 7.10 million but carried a loss of USD 3.10 million and a negative net worth of USD 8.20 million, making the exit a balance sheet cleanup move aligned with UPL's focus on profitable growth.

*this image is generated using AI for illustrative purposes only.
UPL Limited has moved to streamline its portfolio by divesting its entire stake in Bioplanta Nutricao Vegetal Industria e Comercio S.A., a joint venture company, for a nominal consideration of USD 20. The sale was executed by UPL do Brasil Industria e Comercio de Insumos Agropecuarios S.A., a subsidiary of UPL Limited, which secured all necessary regulatory approvals on July 29, 2026. The transaction is expected to be completed on or before July 31, 2026.
The divestment targets an associate company that reported negative financials in FY25. Under IND AS, Bioplanta does not contribute to UPL's consolidated revenue from operations. The move allows the group to exit an entity with a negative net worth, aligning with management's stated focus on profitable growth. The buyers are Marino Jose Franz and Miguel Vaz Ribeiro, Brazilian citizens and businessmen who do not belong to the promoter group or related parties of UPL Limited.
Financial Profile of Bioplanta
Bioplanta is engaged in the manufacture, sale, importation, exportation, and tolling of fertilizers, agrochemicals, adjuvants, and agriculture inputs. Despite generating revenue, the entity operated at a loss during the last financial year. The financial details for FY25 are outlined below:
| Particulars: | Amt (USD Mn) |
|---|---|
| Revenue: | 7.10 |
| Networth: | (8.20) |
| Profit/(Loss): | (3.10) |
The negative net worth of USD 8.20 million and a loss of USD 3.10 million highlight the operational challenges faced by the joint venture. By selling the stake for USD 20, UPL effectively sheds this liability without significant cash outflow or complex restructuring costs.
Regulatory Compliance
UPL Limited disclosed the transaction under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-Pod1/P/CIR//2023/123 dated July 13, 2023. The intimation was submitted to BSE Limited and National Stock Exchange of India Ltd on July 29, 2026. The company confirmed that the transaction does not fall within the ambit of related party transactions and is not part of any Scheme of Arrangement under Regulation 37A of the LODR Regulations.
What the Numbers Show
The divestment reflects a strategic cleanup of the balance sheet rather than a revenue-generating event. While Bioplanta generated USD 7.10 million in revenue in FY25, its inability to convert this into profit—evidenced by a USD 3.10 million loss and negative net worth—made it a drag on the group's overall financial health. Removing such entities simplifies the corporate structure and eliminates ongoing monitoring costs associated with loss-making associates. For investors, the significance lies in the removal of a negative net-worth asset, albeit at a nominal value, signaling a continued focus on core profitability drivers.
Historical Stock Returns for UPL
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.74% | +5.22% | -2.18% | -5.89% | -18.47% | -15.39% |
How will the removal of Bioplanta's negative net worth impact UPL Limited's consolidated balance sheet metrics and debt-to-equity ratios in the upcoming quarter?
Does this divestment signal a broader strategic shift for UPL to exit other underperforming joint ventures or non-core assets in emerging markets?
What specific operational or market factors contributed to Bioplanta's inability to convert USD 7.10 million in revenue into profit, and have these issues been addressed by the new owners?


































